Broccoli Sprouts Found to Boost Body's Ability to Eliminate Cancer-Causing Toxins in Human Study

Broccoli Sprouts Found to Boost Body's Ability to Eliminate Cancer-Causing Toxins in Human Study A team from Johns Hopkins University School of Medicine and Bloomberg School of Public Health, in collaboration with scientists at the Qidong Liver Cancer Institute, Jiao Tong University in Shanghai and the University of Minnesota Cancer Center, in a blinded placebo-controlled study published in the November issue of Cancer Epidemiology Biomarkers & Prevention, have observed that broccoli sprouts can help the body detoxify carcinogens, which may reduce the risk of developing liver cancer. The study used Three-day-old broccoli sprouts with known levels of sulforaphane glucosinolate (SGS(TM)) and involved 200 subjects in total
Home Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P. Natrol Appoints Vincent Andrich VP Sales for Prolab Division Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results Body Shop Reports 24.8 Mil Euro Sales Revenues Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label Supplement Group Targets Consumer Education Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO drugstore.com Expects to Reach Profitability Target in 2003 Human Genome Project Leads to Innovative Healthcare NPIcenter’s Career Center targets nutraceutical Industry Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders Editorial: An Exercise in Synergy NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway Natural Health Trends Corp. Launches Lexxus Taiwan FDA Presents Compliance Guide for Structure/Function Claims New TrimFit® Bars Redefine Energy Bar Category New TrimFit® Bars Redefine Energy Bar Category Probiata® Offers Safe, Natural and Effective Alternative Alive & Well with Michelle Harris Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com Consumers Search for Healthy Cleaning Products That Work Nordic Naturals: Omega 3 Fatty Acids Cyanotech Names Bob Capelli as Director of Sales Medical Journal Publishes Trial Showing Study Results of COLD-fX(R) The Canadian Medical Association Journal will publish results of double-blind, placebo-controlled study on COLD-fX(R) for prevention and relief of upper respiratory infections; results indicate that the number of upper respiratory infections in each subject was significantly reduced by 25%, recurrent infections were reduced by 56%, and treatment also had a significant effect in reducing the total symptom score and the duration of infections. Medical Journal Publishes Trial Showing Study Results of COLD-fX(R) The Canadian Medical Association Journal will publish results of double-blind, placebo-controlled study on COLD-fX(R) for prevention and relief of upper respiratory infections; results indicate that the number of upper respiratory infections in each subject was significantly reduced by 25%, recurrent infections were reduced by 56%, and treatment also had a significant effect in reducing the total symptom score and the duration of infections. Medical Journal Publishes Trial Showing Study Results of COLD-fX(R) The Canadian Medical Association Journal will publish results of double-blind, placebo-controlled study on COLD-fX(R) for prevention and relief of upper respiratory infections; results indicate that the number of upper respiratory infections in each subject was significantly reduced by 25%, recurrent infections were reduced by 56%, and treatment also had a significant effect in reducing the total symptom score and the duration of infections. Medical Journal Publishes Trial Showing Study Results of COLD-fX(R) The Canadian Medical Association Journal will publish results of double-blind, placebo-controlled study on COLD-fX(R) for prevention and relief of upper respiratory infections; results indicate that the number of upper respiratory infections in each subject was significantly reduced by 25%, recurrent infections were reduced by 56%, and treatment also had a significant effect in reducing the total symptom score and the duration of infections. Medical Journal Publishes Trial Showing Study Results of COLD-fX(R) The Canadian Medical Association Journal will publish results of double-blind, placebo-controlled study on COLD-fX(R) for prevention and relief of upper respiratory infections; results indicate that the number of upper respiratory infections in each subject was significantly reduced by 25%, recurrent infections were reduced by 56%, and treatment also had a significant effect in reducing the total symptom score and the duration of infections. New Clinical Trial Demonstrates Effectiveness of SierraSil®, Nutraceutical Mineral Complex for Osteoarthritis Results of double-blind, randomized, placebo-controlled, multi-centered clinical trial, published in the Journal of Inflammation, indicate that SierraSil provided significant symptomatic relief after one week, to patients with osteoarthritis of the knee. New Clinical Trial Demonstrates Effectiveness of SierraSil®, Nutraceutical Mineral Complex for Osteoarthritis Results of double-blind, randomized, placebo-controlled, multi-centered clinical trial, published in the Journal of Inflammation, indicate that SierraSil provided significant symptomatic relief after one week, to patients with osteoarthritis of the knee. New Clinical Trial Demonstrates Effectiveness of SierraSil®, Nutraceutical Mineral Complex for Osteoarthritis Results of double-blind, randomized, placebo-controlled, multi-centered clinical trial, published in the Journal of Inflammation, indicate that SierraSil provided significant symptomatic relief after one week, to patients with osteoarthritis of the knee. New Clinical Trial Demonstrates Effectiveness of SierraSil®, Nutraceutical Mineral Complex for Osteoarthritis Results of double-blind, randomized, placebo-controlled, multi-centered clinical trial, published in the Journal of Inflammation, indicate that SierraSil provided significant symptomatic relief after one week, to patients with osteoarthritis of the knee. New Clinical Trial Demonstrates Effectiveness of SierraSil®, Nutraceutical Mineral Complex for Osteoarthritis Results of double-blind, randomized, placebo-controlled, multi-centered clinical trial, published in the Journal of Inflammation, indicate that SierraSil provided significant symptomatic relief after one week, to patients with osteoarthritis of the knee. Study Examines the Safe Consumption Of Soy Isoflavones As Hormone Replacement Therapy New results, based on studies of an experimental model designed to investigate consumption of soy-derived products as a natural alternative to hormone replacement therapy in post-menopausal breast cancer women, were presented today at the 6th International Symposium on the Role of Soy in Preventing and Treating Chronic Disease; results indicate that consumption of Soyselect® does not stimulate the growth of breast cancer tumors in the experimental model used (xenograft MCF-7). Study Examines the Safe Consumption Of Soy Isoflavones As Hormone Replacement Therapy New results, based on studies of an experimental model designed to investigate consumption of soy-derived products as a natural alternative to hormone replacement therapy in post-menopausal breast cancer women, were presented today at the 6th International Symposium on the Role of Soy in Preventing and Treating Chronic Disease; results indicate that consumption of Soyselect® does not stimulate the growth of breast cancer tumors in the experimental model used (xenograft MCF-7). Study Examines the Safe Consumption Of Soy Isoflavones As Hormone Replacement Therapy New results, based on studies of an experimental model designed to investigate consumption of soy-derived products as a natural alternative to hormone replacement therapy in post-menopausal breast cancer women, were presented today at the 6th International Symposium on the Role of Soy in Preventing and Treating Chronic Disease; results indicate that consumption of Soyselect® does not stimulate the growth of breast cancer tumors in the experimental model used (xenograft MCF-7). Study Examines the Safe Consumption Of Soy Isoflavones As Hormone Replacement Therapy New results, based on studies of an experimental model designed to investigate consumption of soy-derived products as a natural alternative to hormone replacement therapy in post-menopausal breast cancer women, were presented today at the 6th International Symposium on the Role of Soy in Preventing and Treating Chronic Disease; results indicate that consumption of Soyselect® does not stimulate the growth of breast cancer tumors in the experimental model used (xenograft MCF-7). Study Examines the Safe Consumption Of Soy Isoflavones As Hormone Replacement Therapy New results, based on studies of an experimental model designed to investigate consumption of soy-derived products as a natural alternative to hormone replacement therapy in post-menopausal breast cancer women, were presented today at the 6th International Symposium on the Role of Soy in Preventing and Treating Chronic Disease; results indicate that consumption of Soyselect® does not stimulate the growth of breast cancer tumors in the experimental model used (xenograft MCF-7). ForsLean Increases Lean Body Mass and Reduces Body Fat Percentages According to Recent Study 12-week randomized, double-blind, placebo-controlled study of 50 obese men and women revealed that subjects receiving ForsLean had a statistically significant increase in lean body mass of 1.78 percent compared to a 0.20 percent decrease in the placebo group. ForsLean Increases Lean Body Mass and Reduces Body Fat Percentages According to Recent Study 12-week randomized, double-blind, placebo-controlled study of 50 obese men and women revealed that subjects receiving ForsLean had a statistically significant increase in lean body mass of 1.78 percent compared to a 0.20 percent decrease in the placebo group. ForsLean Increases Lean Body Mass and Reduces Body Fat Percentages According to Recent Study 12-week randomized, double-blind, placebo-controlled study of 50 obese men and women revealed that subjects receiving ForsLean had a statistically significant increase in lean body mass of 1.78 percent compared to a 0.20 percent decrease in the placebo group. ForsLean Increases Lean Body Mass and Reduces Body Fat Percentages According to Recent Study 12-week randomized, double-blind, placebo-controlled study of 50 obese men and women revealed that subjects receiving ForsLean had a statistically significant increase in lean body mass of 1.78 percent compared to a 0.20 percent decrease in the placebo group. NIH Study Examines the Efficacy and Safety of Glucosamine and Chondroitin in Promoting Knee Joint Health Initial findings from GAIT study indicate that "combination glucosamine and chondroitin is effective in treating moderate to severe knee pain due to osteoarthritis". NIH Study Examines the Efficacy and Safety of Glucosamine and Chondroitin in Promoting Knee Joint Health Initial findings from GAIT study indicate that "combination glucosamine and chondroitin is effective in treating moderate to severe knee pain due to osteoarthritis". NIH Study Examines the Efficacy and Safety of Glucosamine and Chondroitin in Promoting Knee Joint Health Initial findings from GAIT study indicate that "combination glucosamine and chondroitin is effective in treating moderate to severe knee pain due to osteoarthritis". NIH Study Examines the Efficacy and Safety of Glucosamine and Chondroitin in Promoting Knee Joint Health Initial findings from GAIT study indicate that "combination glucosamine and chondroitin is effective in treating moderate to severe knee pain due to osteoarthritis". NIH Study Examines the Efficacy and Safety of Glucosamine and Chondroitin in Promoting Knee Joint Health Initial findings from GAIT study indicate that "combination glucosamine and chondroitin is effective in treating moderate to severe knee pain due to osteoarthritis". NIH Study Examines the Efficacy and Safety of Glucosamine and Chondroitin in Promoting Knee Joint Health Initial findings from GAIT study indicate that "combination glucosamine and chondroitin is effective in treating moderate to severe knee pain due to osteoarthritis". NIH-Sponsored Trial Shows Supplements Relieve Arthritis Pain Council for Responsible Nutrition comments on recently released clinical trial results of glucosamine and chondroitin and pain relief from osteoarthritis. NIH-Sponsored Trial Shows Supplements Relieve Arthritis Pain Council for Responsible Nutrition comments on recently released clinical trial results of glucosamine and chondroitin and pain relief from osteoarthritis. NIH-Sponsored Trial Shows Supplements Relieve Arthritis Pain Council for Responsible Nutrition comments on recently released clinical trial results of glucosamine and chondroitin and pain relief from osteoarthritis. NIH-Sponsored Trial Shows Supplements Relieve Arthritis Pain Council for Responsible Nutrition comments on recently released clinical trial results of glucosamine and chondroitin and pain relief from osteoarthritis. NIH-Sponsored Trial Shows Supplements Relieve Arthritis Pain Council for Responsible Nutrition comments on recently released clinical trial results of glucosamine and chondroitin and pain relief from osteoarthritis. New Findings Suggest Keratin Ingredient Cynatine FLX Activates Joint Defense Enzymes Recent laboratory research on rats suggests that the new keratin joint ingredient Cynatine FLX activates two important joint antioxidant defense enzymes (glutathione peroxidase (GSH-PX) and superoxide dismutase (SOD)) and stimulates the regeneration of cells. New Findings Suggest Keratin Ingredient Cynatine FLX Activates Joint Defense Enzymes Recent laboratory research on rats suggests that the new keratin joint ingredient Cynatine FLX activates two important joint antioxidant defense enzymes (glutathione peroxidase (GSH-PX) and superoxide dismutase (SOD)) and stimulates the regeneration of cells. New Findings Suggest Keratin Ingredient Cynatine FLX Activates Joint Defense Enzymes Recent laboratory research on rats suggests that the new keratin joint ingredient Cynatine FLX activates two important joint antioxidant defense enzymes (glutathione peroxidase (GSH-PX) and superoxide dismutase (SOD)) and stimulates the regeneration of cells. New Findings Suggest Keratin Ingredient Cynatine FLX Activates Joint Defense Enzymes Recent laboratory research on rats suggests that the new keratin joint ingredient Cynatine FLX activates two important joint antioxidant defense enzymes (glutathione peroxidase (GSH-PX) and superoxide dismutase (SOD)) and stimulates the regeneration of cells. New Findings Suggest Keratin Ingredient Cynatine FLX Activates Joint Defense Enzymes Recent laboratory research on rats suggests that the new keratin joint ingredient Cynatine FLX activates two important joint antioxidant defense enzymes (glutathione peroxidase (GSH-PX) and superoxide dismutase (SOD)) and stimulates the regeneration of cells. Clinical Study Finds Ginkgo Extract EGb 761(R) Improves Quality of Life of Typical Alzheimer's Patients Results of the double-blind, placebo-controlled trial were presented at the 21st International Conference of Alzheimer's Disease International, indicate that Ginkgo biloba extract EGb 761(R) (manufactured by the Dr. Willmar Schwabe Company), improve cognitive functions, neuropsychiatric symptoms and the ability to perform daily living activities among typical Alzheimer's patients. Clinical Study Finds Ginkgo Extract EGb 761(R) Improves Quality of Life of Typical Alzheimer's Patients Results of the double-blind, placebo-controlled trial were presented at the 21st International Conference of Alzheimer's Disease International, indicate that Ginkgo biloba extract EGb 761(R) (manufactured by the Dr. Willmar Schwabe Company), improve cognitive functions, neuropsychiatric symptoms and the ability to perform daily living activities among typical Alzheimer's patients. Clinical Study Finds Ginkgo Extract EGb 761(R) Improves Quality of Life of Typical Alzheimer's Patients Results of the double-blind, placebo-controlled trial were presented at the 21st International Conference of Alzheimer's Disease International, indicate that Ginkgo biloba extract EGb 761(R) (manufactured by the Dr. Willmar Schwabe Company), improve cognitive functions, neuropsychiatric symptoms and the ability to perform daily living activities among typical Alzheimer's patients. Clinical Study Finds Ginkgo Extract EGb 761(R) Improves Quality of Life of Typical Alzheimer's Patients Results of the double-blind, placebo-controlled trial were presented at the 21st International Conference of Alzheimer's Disease International, indicate that Ginkgo biloba extract EGb 761(R) (manufactured by the Dr. Willmar Schwabe Company), improve cognitive functions, neuropsychiatric symptoms and the ability to perform daily living activities among typical Alzheimer's patients. Clinical Study Finds Ginkgo Extract EGb 761(R) Improves Quality of Life of Typical Alzheimer's Patients Results of the double-blind, placebo-controlled trial were presented at the 21st International Conference of Alzheimer's Disease International, indicate that Ginkgo biloba extract EGb 761(R) (manufactured by the Dr. Willmar Schwabe Company), improve cognitive functions, neuropsychiatric symptoms and the ability to perform daily living activities among typical Alzheimer's patients. Study: Chromium Picolinate May Provide Cardiovascular Benefits in Pre-Diabetes Preclinical study on rats, conducted at the University of Alberta, and presented at the 3rd World Congress on Insulin Resistance Syndrome, shows daily use of chromium picolinate provides significant cardiovascular benefits in pre-diabetic rats that have insulin resistance Study: Chromium Picolinate May Provide Cardiovascular Benefits in Pre-Diabetes Preclinical study on rats, conducted at the University of Alberta, and presented at the 3rd World Congress on Insulin Resistance Syndrome, shows daily use of chromium picolinate provides significant cardiovascular benefits in pre-diabetic rats that have insulin resistance Study: Chromium Picolinate May Provide Cardiovascular Benefits in Pre-Diabetes Preclinical study on rats, conducted at the University of Alberta, and presented at the 3rd World Congress on Insulin Resistance Syndrome, shows daily use of chromium picolinate provides significant cardiovascular benefits in pre-diabetic rats that have insulin resistance Study: Chromium Picolinate May Provide Cardiovascular Benefits in Pre-Diabetes Preclinical study on rats, conducted at the University of Alberta, and presented at the 3rd World Congress on Insulin Resistance Syndrome, shows daily use of chromium picolinate provides significant cardiovascular benefits in pre-diabetic rats that have insulin resistance Study: Chromium Picolinate May Provide Cardiovascular Benefits in Pre-Diabetes Preclinical study on rats, conducted at the University of Alberta, and presented at the 3rd World Congress on Insulin Resistance Syndrome, shows daily use of chromium picolinate provides significant cardiovascular benefits in pre-diabetic rats that have insulin resistance Study: Chromium Picolinate May Provide Cardiovascular Benefits in Pre-Diabetes Preclinical study on rats, conducted at the University of Alberta, and presented at the 3rd World Congress on Insulin Resistance Syndrome, shows daily use of chromium picolinate provides significant cardiovascular benefits in pre-diabetic rats that have insulin resistance Body Of Science Supporting Astaxanthin For Eye Fatigue Reaches Critical Mass According to the company, there are now seven published human clinical studies relating astaxanthin to this benefit, all performed using AstaREAL® natural astaxanthin. Body Of Science Supporting Astaxanthin For Eye Fatigue Reaches Critical Mass According to the company, there are now seven published human clinical studies relating astaxanthin to this benefit, all performed using AstaREAL® natural astaxanthin. Body Of Science Supporting Astaxanthin For Eye Fatigue Reaches Critical Mass According to the company, there are now seven published human clinical studies relating astaxanthin to this benefit, all performed using AstaREAL® natural astaxanthin. Body Of Science Supporting Astaxanthin For Eye Fatigue Reaches Critical Mass According to the company, there are now seven published human clinical studies relating astaxanthin to this benefit, all performed using AstaREAL® natural astaxanthin. Glucosamine Studied in Mouse Model of Multiple Sclerosis Using a mouse model of Multiple Sclerosis (MS) in an animal study published in the Journal of Immunology, glucosamine dramatically delayed the onset of symptoms and improved the animal's ability to move and walk. Glucosamine Studied in Mouse Model of Multiple Sclerosis Using a mouse model of Multiple Sclerosis (MS) in an animal study published in the Journal of Immunology, glucosamine dramatically delayed the onset of symptoms and improved the animal's ability to move and walk. Glucosamine Studied in Mouse Model of Multiple Sclerosis Using a mouse model of Multiple Sclerosis (MS) in an animal study published in the Journal of Immunology, glucosamine dramatically delayed the onset of symptoms and improved the animal's ability to move and walk. Glucosamine Studied in Mouse Model of Multiple Sclerosis Using a mouse model of Multiple Sclerosis (MS) in an animal study published in the Journal of Immunology, glucosamine dramatically delayed the onset of symptoms and improved the animal's ability to move and walk. Glucosamine Studied in Mouse Model of Multiple Sclerosis Using a mouse model of Multiple Sclerosis (MS) in an animal study published in the Journal of Immunology, glucosamine dramatically delayed the onset of symptoms and improved the animal's ability to move and walk. Study Finds Omega-3 Fatty Acids Help Decrease Postpartum Depression randomized dose-ranging pilot trial of Omega-3 fatty acids for post-partum depression indicates that scores on depression measures decreased by approximately 50 percent, and were statistically significant. Study Finds Omega-3 Fatty Acids Help Decrease Postpartum Depression randomized dose-ranging pilot trial of Omega-3 fatty acids for post-partum depression indicates that scores on depression measures decreased by approximately 50 percent, and were statistically significant. Study Finds Omega-3 Fatty Acids Help Decrease Postpartum Depression randomized dose-ranging pilot trial of Omega-3 fatty acids for post-partum depression indicates that scores on depression measures decreased by approximately 50 percent, and were statistically significant. Study Finds Omega-3 Fatty Acids Help Decrease Postpartum Depression randomized dose-ranging pilot trial of Omega-3 fatty acids for post-partum depression indicates that scores on depression measures decreased by approximately 50 percent, and were statistically significant. Study Finds Omega-3 Fatty Acids Help Decrease Postpartum Depression randomized dose-ranging pilot trial of Omega-3 fatty acids for post-partum depression indicates that scores on depression measures decreased by approximately 50 percent, and were statistically significant. Study Examines Ability of Vitamin To Help Treatment-resistant Asthma Researchers from King's College London have found that vitamin D3 could substantially improve the responsiveness of these patients to steroid treatment for asthma attacks. Study Examines Ability of Vitamin To Help Treatment-resistant Asthma Researchers from King's College London have found that vitamin D3 could substantially improve the responsiveness of these patients to steroid treatment for asthma attacks. Study Examines Ability of Vitamin To Help Treatment-resistant Asthma Researchers from King's College London have found that vitamin D3 could substantially improve the responsiveness of these patients to steroid treatment for asthma attacks. Study Examines Ability of Vitamin To Help Treatment-resistant Asthma Researchers from King's College London have found that vitamin D3 could substantially improve the responsiveness of these patients to steroid treatment for asthma attacks. Vitamin D Can Play Role in Lung Health study in the December issue of CHEST shows that patients with higher concentrations of vitamin D had significantly better lung function, compared with patients with lower concentrations of vitamin D. Vitamin D Can Play Role in Lung Health study in the December issue of CHEST shows that patients with higher concentrations of vitamin D had significantly better lung function, compared with patients with lower concentrations of vitamin D. Vitamin D Can Play Role in Lung Health study in the December issue of CHEST shows that patients with higher concentrations of vitamin D had significantly better lung function, compared with patients with lower concentrations of vitamin D. Vitamin D Can Play Role in Lung Health study in the December issue of CHEST shows that patients with higher concentrations of vitamin D had significantly better lung function, compared with patients with lower concentrations of vitamin D. Omega-3 Fatty Acids Can Improve Lung Function Japanese researchers find that a diet rich in omega-3 fatty acids can have anti-inflammatory effects and improve the exercise capacity for patients with chronic obstructive pulmonary disease (COPD). Omega-3 Fatty Acids Can Improve Lung Function Japanese researchers find that a diet rich in omega-3 fatty acids can have anti-inflammatory effects and improve the exercise capacity for patients with chronic obstructive pulmonary disease (COPD). Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology. Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology. Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Heart Health Alert: Niacin May Reverse Hardening of the Arteries Heart Health Alert: Niacin May Reverse Hardening of the Arteries Heart Health Alert: Niacin May Reverse Hardening of the Arteries Heart Health Alert: Niacin May Reverse Hardening of the Arteries Spotlight on Savory Side Dishes Spotlight on Savory Side Dishes Spotlight on Savory Side Dishes Another Reason to Choose Healthy Lifestyle Habits Another Reason to Choose Healthy Lifestyle Habits	BALTIMORE, Nov. 16 /CNW/ -- A human trial conducted in China shows broccoli sprouts can help the body detoxify carcinogens, which may reduce the risk of developing liver cancer. A team from Johns Hopkins University School of Medicine and Bloomberg School of Public Health, in collaboration with scientists at the Qidong Liver Cancer Institute, Jiao Tong University in Shanghai and the University of Minnesota Cancer Center, conducted the study. It is published in the November issue of Cancer Epidemiology Biomarkers & Prevention. This is the first study to provide direct evidence that broccoli sprouts can enhance the body's detoxifying system to help prevent cancer. Although previous laboratory studies indicated this was true, this is the first time that a direct observation of this effect in humans was possible. The blinded, placebo-controlled study was conducted in Jiangsu Province near Shanghai, a rural area where the incidence of liver cancer is extremely high due to consumption of foods tainted with aflatoxin, a powerful carcinogen produced by mold contaminating the grain that the population grows and eats. The toxin binds to DNA and becomes a chemical indicator, or biomarker, for an increased risk of developing liver cancer. Three-day-old broccoli sprouts with known levels of sulforaphane glucosinolate (SGS(TM)) were grown at the site in China and prepared as a liquid extract to ensure standard dosages. One hundred test subjects drank five ounces of the extract (equivalent to eating about two ounces of broccoli sprouts) each day for two weeks. A control group drank a similar extract that contained virtually no SGS. Tests of subjects' urine showed carcinogens were being detoxified and removed from the body in those who drank the SGS extract. As the levels of sulforaphane derivatives in the urine increased, the amount of DNA damage decreased, which may indicate a reduction in cancer risk. "While this study did not directly look at liver cancer, it is clear that liver cancer has had devastating consequences in this region of China and in other parts of the world. This study is an initial step in evaluating dietary methods for preventing this disease, and it may be applicable to other types of cancers," said participating epidemiologist Jian-Guo Chen, M.D., of the Qidong Liver Cancer Institute. Further studies are in the planning phases to examine dose levels and implications for other high-risk populations. In 1992, scientists at Johns Hopkins first determined that broccoli contained high levels of the long-lasting antioxidant sulforaphane. In 1997, they discovered that three-day-old broccoli sprouts contained more than a 20 times higher concentration of SGS than mature broccoli. More than 350 studies have appeared in peer-reviewed scientific publications pointing to sulforaphane and SGS from broccoli and broccoli sprouts as powerful health protectors. Broccoli sprouts are available in the produce sections of most major supermarkets in the U.S. under the name BroccoSprouts(R), grown naturally with technology licensed from Johns Hopkins University School of Medicine. BroccoSprouts contain measured and consistent levels of SGS, the natural detoxifying compound reported upon in this study. A portion of the gross sales of BroccoSprouts is donated to the Brassica Foundation to support further research on chemoprotection. For more information, visit www.broccosprouts.com. Source: Thomas W. Kensler, Jian-Guo Chen, Patricia A. Egner, Jed W. Fahey, Lisa P. Jacobson, Katherine K. Stephenson, Lingxiang Ye, Jamie L. Coady, Jin-Bing Wang, Yan Wu, Yan Sun, Qi-Nan Zhang, Bao-Chu Zhang, Yuan-Rong Zhu, Geng-Sun Qian, Stephen G. Carmella, Stephen S. Hecht, Lorie Benning, Stephen J. Gange, John D. Groopman, and Paul Talalay. "Effects of Glucosinolate-Rich Broccoli Sprouts on Urinary Levels of Aflatoxin-DNA Adducts and Phenanthrene Tetraols in Randomized Clinical Trial in He Zuo Township, Quidong, China." Cancer Epidemiology Biomarkers & Prevention, Vol. 14, Issue 11, pp. 2605-2613 November 1, 2005. Under a licensing agreement between Brassica Protection Products LLC (BPP) and the Johns Hopkins University, Drs. Paul Talalay and Jed Fahey, who are co-authors on the paper, are entitled to shares of royalty received by the University on sales of products described in this article. Drs. Talalay and Fahey own BPP stock, which is subject to certain restrictions under University policy. Drs. Talalay and Fahey are unpaid consultants to the company. Dr. Talalay's son is the Chief Executive Officer of BPP and owns BPP stock. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.
Powered By Traffic Booster Absolute News Manager Plug-in by Xigla Software